These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 33533311)

  • 1. Exercise decreases aberrant corticostriatal plasticity in an animal model of l-DOPA-induced dyskinesia.
    Speck AE; Aguiar AS; Ferreira SG; Silva HB; Tomé ÂR; Agostinho P; Cunha RA; Prediger RD
    Am J Physiol Regul Integr Comp Physiol; 2021 Apr; 320(4):R541-R546. PubMed ID: 33533311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derangement of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) and extracellular signal-regulated kinase (ERK) dependent striatal plasticity in L-DOPA-induced dyskinesia.
    Cerovic M; Bagetta V; Pendolino V; Ghiglieri V; Fasano S; Morella I; Hardingham N; Heuer A; Papale A; Marchisella F; Giampà C; Calabresi P; Picconi B; Brambilla R
    Biol Psychiatry; 2015 Jan; 77(2):106-15. PubMed ID: 24844602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
    Aguiar AS; Moreira EL; Hoeller AA; Oliveira PA; Córdova FM; Glaser V; Walz R; Cunha RA; Leal RB; Latini A; Prediger RD
    Neuroscience; 2013 Jul; 243():46-53. PubMed ID: 23558088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
    Shen W; Plotkin JL; Francardo V; Ko WK; Xie Z; Li Q; Fieblinger T; Wess J; Neubig RR; Lindsley CW; Conn PJ; Greengard P; Bezard E; Cenci MA; Surmeier DJ
    Neuron; 2015 Nov; 88(4):762-73. PubMed ID: 26590347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models.
    Thiele SL; Chen B; Lo C; Gertler TS; Warre R; Surmeier JD; Brotchie JM; Nash JE
    Neurobiol Dis; 2014 Nov; 71():334-44. PubMed ID: 25171793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.
    Suárez LM; Solís O; Caramés JM; Taravini IR; Solís JM; Murer MG; Moratalla R
    Biol Psychiatry; 2014 May; 75(9):711-22. PubMed ID: 23769604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher free D-aspartate and N-methyl-D-aspartate levels prevent striatal depotentiation and anticipate L-DOPA-induced dyskinesia.
    Errico F; Bonito-Oliva A; Bagetta V; Vitucci D; Romano R; Zianni E; Napolitano F; Marinucci S; Di Luca M; Calabresi P; Fisone G; Carta M; Picconi B; Gardoni F; Usiello A
    Exp Neurol; 2011 Dec; 232(2):240-50. PubMed ID: 21946266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
    Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treadmill Exercise Attenuates L-DOPA-Induced Dyskinesia and Increases Striatal Levels of Glial Cell-Derived Neurotrophic Factor (GDNF) in Hemiparkinsonian Mice.
    Speck AE; Schamne MG; S Aguiar A; Cunha RA; Prediger RD
    Mol Neurobiol; 2019 Apr; 56(4):2944-2951. PubMed ID: 30073506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nociceptive Response to L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats.
    Nascimento GC; Bariotto-Dos-Santos K; Leite-Panissi CRA; Del-Bel EA; Bortolanza M
    Neurotox Res; 2018 Nov; 34(4):799-807. PubMed ID: 29611150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat.
    Lindenbach D; Ostock CY; Eskow Jaunarajs KL; Dupre KB; Barnum CJ; Bhide N; Bishop C
    J Pharmacol Exp Ther; 2011 Jun; 337(3):755-65. PubMed ID: 21402691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia.
    Picconi B; Centonze D; Håkansson K; Bernardi G; Greengard P; Fisone G; Cenci MA; Calabresi P
    Nat Neurosci; 2003 May; 6(5):501-6. PubMed ID: 12665799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectral signatures of L-DOPA-induced dyskinesia depend on L-DOPA dose and are suppressed by ketamine.
    Ye T; Bartlett MJ; Sherman SJ; Falk T; Cowen SL
    Exp Neurol; 2021 Jun; 340():113670. PubMed ID: 33662379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment.
    Belujon P; Lodge DJ; Grace AA
    Mov Disord; 2010 Aug; 25(11):1568-76. PubMed ID: 20623773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
    Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z
    Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A positive allosteric modulator of mGlu4 receptors restores striatal plasticity in an animal model of l-Dopa-induced dyskinesia.
    Calabrese V; Picconi B; Heck N; Campanelli F; Natale G; Marino G; Sciaccaluga M; Ghiglieri V; Tozzi A; Anceaume E; Cuoc E; Caboche J; Conquet F; Calabresi P; Charvin D
    Neuropharmacology; 2022 Nov; 218():109205. PubMed ID: 35940348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
    BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice.
    Won L; Ding Y; Singh P; Kang UJ
    J Neurosci; 2014 Feb; 34(8):3090-4. PubMed ID: 24553948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.